Analysis of human blood monocyte activation at the level of gene expression. Expression of alpha interferon genes during activation of human monocytes by poly IC/LC and muramyl dipeptide by unknown
ANALYSIS  OF  HUMAN  BLOOD  MONOCYTE  ACTIVATION 
AT  THE  LEVEL  OF  GENE  r EXPRESSION 
Expression of Alpha Interferon Genes During Activation of Human 
Monocytes by Poly IC/LC and Muramyl Dipeptide 
BY  HENRY C.  STEVENSON,  GREGORY A. DEKABAN,*  PAUL J.  MILLER, 
CHEEPTIP BENYAJATI,* AND  MARK L.  PEARSON* 
From the Biological Therapeutics Branch, Biological Response Modifiers Program, and *Ojfice 
of the Director, National Cancer Institute,  and the *Laboratory of Molecular Biology, Litton 
Bionetics, Inc., NCI-FCRF, Frederick, Maryland 21701 
Human  monocytes have  been  shown  to  be  critical regulatory cells  in  the 
immune response. Their functions include antigen presentation (1), the genera- 
tion  of cytolytic T  lymphocyte responses  (2,  3),  and  various  accessory  cell 
functions (4). Monocytes have a number of other effector functions, including 
the performance of  antibody-dependent cellular cytotoxicity (5), and spontaneous 
tumoricidai activity (6,  7). Monocytes exert a number of their stimulatory and 
modulatory activities on other components of the immune response by releasing 
highly bioactive molecules, including prostaglandins (8), interleukin 1 (IL-1) (4, 
9), a-interferon (IFN-a) ~ (10, 11), and superoxide (O~) (12). In addition, mono- 
cytes are known to also be capable of secreting dozens of other potent cytokines 
(13), including fibroblast growth factor(s) (FGF) (14, 15). 
Our current understanding of monocyte and macrophage activation centers 
more around the nature of the effective stimuli for functional changes than 
around  the regulatory mechanisms responsible for the development of these 
functions (16, 17-19). In view of the potential clinical importance of understand- 
ing the mechanisms regulating the expression of different aspects of the monocyte 
functional repertoire, we have begun an investigation of the molecular basis of 
monocyte activation. Here we report the results of studies on IFN-a production 
and  release  in  human  monocytes after  exposure  to  two  different  activation 
agents, poly IC/LC and muramyl dipeptide. 
Materials and Methods 
Leukapheresis  Technique.  Leukapheresis was performed on normal volunteers for 2 h 
on a Celltrifuge II apparatus (Fenwal Laboratories, Deerfield, IL) after informed consent 
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as previously described (20). We eliminated donors who had any history of atopy or other 
immunologic disorders, drug ingestion of any sort (including aspirin or birth control pills), 
or abnormalities on physical or laboratory examinations. 
Monocyte Isolation.  Monocytes were isolated from the above leukapheresis specimens 
by countercurrent centrifugal elutriation as previously described (21). Briefly, leukapher- 
esis specimens were passed over standard Ficoll-Hypaque gradients to produce an unfrac- 
tionated mononuclear leukocyte suspension. These leukocyte cell preparations were then 
suspended in elutriation medium (RPMI  1640 [Flow  Laboratories, Inc.,  McLean, VA] 
with  2  g/100  ml  of human  clinical  grade human  albumin  [Cutter  Laboratories, Inc., 
Berkeley, CA] with a final pH of 7.4) and entered with a Sarns cardiovascular pump into 
a Beckman JE6 elutriation chamber and rotor system (Beckman Instruments, Inc., Palo 
Alto, CA) at an initial medium flow rate of 5 ±  0.4 mi/min. The elutriation rotor speed 
was maintained at 2,020 --. 10 rpm, and the centrifuge temperature was held at  18°C. 
Elutriation medium leaving the elutriator rotor was collected in 50-ml aliquots in polypro- 
pylene conical centrifuge tubes (Corning Glass Works, Coming, NY), and the cells in each 
aliquot were sized by a Coulter H4 channelizer system (Coulter Electronics, Hialeah, FL). 
The flow rate of medium was gradually increased until equal numbers of lymphocytes 
and monocytes were seen to be leaving the separation chamber (as determined by Coulter 
channelizer analysis), and the 50-ml aliquot with the above-described 50:50 lymphocyte/ 
monocyte ratio  became  the  penultimate  aliquot  of the  isolation  procedure.  Purified 
monocytes left in the rotor were then collected by stopping the rotor while maintaining 
constant medium flow rate. All of the fractions containing lymphocytes alone were pooled 
to obtain purified lymphocytes. The final medium flow rate, 12 +  0.4 ml/min, and the 
total number of 50-ml aliquots collected (from 9 to 15) varied depending on the elutriation 
characteristics of each donor's mononuclear leukocytes. An average of 5 h elapsed from 
the start of leukapheresis until the final isolation of purified monocytes. All medium used 
was endotoxin free (<0.1 ng/ml of endotoxin, by iimulus assay) and no antibiotics were 
added to any stage of the monocyte isolation procedure. 
Monocyte and Lymphocyte Identification  Procedures.  The purity of the monocyte and 
lymphocyte  preparations  obtained  by  elutriation  was  confirmed  by  morphology  on 
Wright's-stained cytocentrifuge preparations, by nonspecific esterase staining (22), and by 
the ability to ingest latex particles. Viability was determined to be :>98% by trypan blue 
dye exclusion. The average purity of the  monocytes used  in  this  study,  by Wright's 
staining, was 93%; by esterase staining, 92%; and by latex ingestion, 93%. The average 
number of monocytes obtained per donor was 650 million (data not shown). 
Serum-free Medium.  Human monocytes were cultured and activated in a  chemically 
defined,  serum-free  medium  as  previously described  (23).  This  consisted  of Iscove's 
modified Dulbecco's medium supplemented with human serum albumin (fatty acid free, 
4 mg/ml), cholesterol (>90% pure, 20 mg/ml), L-a-phosphatidylcholine (80 U/ml), and 
human transferrin (98% pure,  1 U]ml), all from Sigma Chemical Company (St.  Louis, 
MO);  insulin (0.128  U/ml;  Eli  Lilly and  Co.,  Indianapolis,  IN);  ferrous chloride (7  × 
10-x~;  Fisher Scientific Co., Pittsburgh, PA); and ¢~-mercaptoethanol  (10  -r M; Eastman 
Kodak,  Rochester,  NY).  The  L-~-phosphatidylcholine and  cholesterol were  prepared 
together and sonicated with a Branson sonifier (Branson Sonic Power Co., Danbury, CT) 
with a microtip at a setting of 6, for 60 rain at 4°C. This preparation, like the others, was 
then filtered (0.45 t~m; Nalge Co., Rochester, NY) and stored at -20°C. 
Monocyte Culture and Activation.  Human, elutriator-purified monocytes were cultured 
in  Custom-designed,  flat-bottomed Teflon labware  (Corning  Glass  Works)  capable  of 
holding 2-40-ml volumes of fluid. Monocytes were suspended at 1 million celis/mi in the 
above-described, serum-free medium, placed in the Teflon plates, and then rocked (7 
cycles/min) in a 37 ° C, 5% COs incubator. For activation of IFN-c~ secretion, monocytes 
were stimulated for 4 h with 10-200 ~g/ml of polyriboinosinic acid/polyribocytidylic  acid 
(2 mg/ml), poly-L-lysine (1.5 mg/ml), and sodium carboxymethyicellulose  (5 mg/ml) (pH, 
7.8) (poly IC/LC) (lot UI82-105; University of Iowa College of Pharmacy, Iowa City, IA). 
To activate  FGF  release,  monocytes were  stimulated  for 4  h  with  15-150  ~g/ml  of 
muramyl dipeptide (MDP) (Calbiochem-Behring Corp., La Jolla, CA). At the end of 18 h STEVENSON  ET  AL.  505 
of culture and after determining cell counts and viability with trypan blue as previously 
described  (22),  we  harvested  both  stimulated  and  unstimulated  monocytes  for  RNA 
separation. For the monokine-release assays (IFN-a and FGF), monocytes were cultured 
as  above  for  18-72  h,  the  supernatants  were  harvested,  and  monokine  assays  were 
performed on supernatants. 
IFN-a Bioassay.  IFN-a activity of culture supernatants was determined by Biofluids, 
Inc. (Rockville, MD) in microtiter plates by inhibition of the cytopathic effect on human 
foreskin cells infected with vesicular stomatitis virus and is expressed in reference standard 
units (10).  Reference human IFN-a (HulFN-a) was supplied by the National Institute of 
Allergy and Infectious Diseases (NIAID). IFN-a activity was confirmed by assaying for 
pH 2  stability and by neutralization  with a  sheep anti-human  leukocyte IFN antibody 
(NIAID Research  Resources Branch  Cat.  No.  G026-502-568  [10]);  this antiserum has 
been shown to inhibit  95%  of the activity of a recombinant HuIFN-a preparation, but 
<10% of the activity of a recombinant HuIFN-B preparation. 
IFN-ct  Bioassay on  Cell  Lysates.  To  determine  whether  bioactive  IFN-a  was  being 
synthesized in the cell cytoplasm, 2.5 x  107 control or activated monocytes were cultured 
as described above.  At  the end  of 36  or  72  h,  the cells were extensively washed and 
suspended in  1 mi of RPMI  1640. The cell suspension was then lysed by freeze-thawing 
(twice),  and cellular debris was pelleted by centrifugation at  1,000 g  for  15  min.  The 
supernatant was then assayed for IFN-a activity as described above; the lower limit of 
sensitivity of this assay is 120 U of IFN-a activity per milliliter of cell cytoplasm. Data are 
expressed in  units  defined as the  IFN-a activity calculated to be in  1 ml of cytoplasm 
obtained from 109 cells. 
FGF Assay.  Supernatants were assayed for FGF activity by a  fibroblast proliferation 
assay as recently described (24).  Fibroblast proliferation was measured as the amount of 
3  trichloroacetic  acid  (TCA)-precipitable  [ H]thymidine  (6.7  #Ci/mmoi)  (New  England 
Nuclear, Boston, MA) counts incorporated into fibroblasts after a 24-h exposure of each 
well (104 cells) to 1 #Ci of [3H]thymidine. 
BNA Extraction  Procedure.  For each data point tested,  400  million purified human 
monocytes were harvested after 18 h of culture. Total cellular RNA was extracted from 
these  cells  by  the  guanidinium  isothiocyanate/cesium  chloride  extraction  method  of 
Ullrich et al. (25). Poly(A)enriched RNA was obtained by passing total RNA over oligo(dT) 
columns as previously described (26). 
Gel Electrophoresis and Northern  Transfer of  Messenger RNA.  Messenger RNA extracted 
from 400 million human monocytes was separated by gel electrophoresis (~2 ~g/sample 
well) using glyoxal as the denaturing agent and a 1.0% agarose gel as described by Thomas 
(27).  After 8  h  of electrophoresis, the gel was blotted onto nitrocellulose sheets by the 
Northern transfer technique as previously described (27).  Ribosomal RNA size markers 
from Escherichia coli (16S,  1.5 kb; 23S, 2.9 kb) and human monocytes (18S,  1.7 kb; 28S, 
4.8 kb) were electrophoresed in a parallel lane. Alternatively, the poly(A)enriched RNA 
from 100 million monocytes or lymphocytes was dot-blotted directly onto nitrocellulose 
sheets as previously described (27); denatured IFN-a cDNA probe was used as the positive 
control. Serial fourfold dilutions of the plasmid DNA and RNA samples were used. 
IFN-a cDNA Probes.  pLM001, a subclone of a previously described (28) cDNA probe 
for human IFN-a~ (pAS-I), which was developed by Dr. Lester May (currently at Stony 
Brook  University in  New  York)  while  working at  Enzo  Biochemicals (New  York)  in 
association with The Rockefeller University, New York, was kindly provided to us by Dr. 
Pravinkumar Sehgal (The Rockefeller University). In addition, through the kindness of 
Dr.  Richard  Derynck (Genentech,  Inc.,  South  San  Francisco,  CA),  we  used  a  second 
previously described IFN-a2 cDNA probe (HuIFN-a~) (29).  These IFN-a cDNA probes 
were labeled with [s2P]dCTP and [3~P]dATP (>400 Ci/mmol; Amersham Corp., Arlington 
Heights, IL) by nick translation, as previously described (30), at a specific activity of 2-3 
x  108 cpm/#g DNA. 
RNA Blotting and Hybridization  Procedure.  Monocyte RNA was transferred from the 
1.0%  agarose gel to nitrocellulose sheets as previously described (27).  Hybridization of 
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under the following relaxed conditions: the 24-h prehybridization and 72-11 hybridizations 
were performed in 6× standard sodium citrate (SSC) (1× SSC is 0.15 M NaCI,  0.015 M 
sodium citrate, pH  7.0),  5×  Denhardt's (lx  Denhart's is 0.02%  "  pyrolidone,  50%POlyvmy  I 
0.02% Ficoll, and 0.02% bovine serum albumin [fraction 5]),  formamide, 100 #g] 
ml of yeast RNA, and 40 #g]ml of sheared, single-stranded salmon sperm DNA, at 37°C. 
Blots were hybridized with 1 ×  107 cpm of labeled probe (boiled for 10 rain). Blots were 
then washed four times in 2)< SSC, with agitation, for 5 rain each at room temperature, 
followed by washing twice in 0.5× SSC plus 0.1% sodium dodecyl sulfate (SDS) for 20 
min at 45°C.  Blots were exposed on either Kodak XAR-5 or DuPont Cronex-4 x-ray 
film, with DuPont Lightning-Plus intensifying screens, at -70°C for 72 h. 
Statistics.  The Student's t test was used to analyze the significance of certain of our 
data. 
Results 
Production  of IFN-ot  and FGF by Activated Human Monocytes.  Fig.  1 demon- 
strates the amount of IFN-a  released by monocytes at  36  h  when cultured in 
serum-free medium under three sets of conditions: unstimulated, after exposure 
to  10-200 t~g/ml of MDP, or after exposure to  10-200 #g/mi of poly IC/LC. 
Although  unactivated  monocytes and  MDP-treated  monocytes did not secrete 
IFN-a, poly IC/LC induced a  dose-responsive secretion of IFN-0t, up to 5.5  × 
102 U/ml. IFN-a secretion occurred as early as 18 h and as late as 72 h (data not 
shown); the maximal rate of secretion was observed at 36 h. In contrast, whereas 
both control and poly IC/LC-stimulated monocytes produced low baseline levels 
of FGF,  MDP-stimulated monocytes (200 t~g/mi) produced approximately four 
times the baseline amount of FGF at 36 h  after stimulation (Fig. 2). 
RNA Extraction.  Monocytes were harvested after 18 h of culture and the total 
RNA  was  harvested by  the  guanidinium/cesium  chloride  isolation  technique. 
This time point was selected because it corresponded to the initiation of IFN-a 
release.  There  was  no  significant  difference in  the  overall recovery of RNA 
6o17 
500 
! 
3OO 
<( 
| 
_= 
lOO 
o  1 
Mom)s  + 
10 ~4~ml 
Poiy I:CILC 
~  I--'t  r---1 
.o,,o.  ~  ÷  a.,~÷  ao...  ÷  .o.,.  +  .N,, 
Alone  10 i,~ml  S0 14gml  2OQ ~*g4ml  ~  ~1  ~  t~ml 
MOP  MOP  MDP  Po~y I:CfLC  Poiy I:CILC 
FIGURE  1.  Human monocytes were cultured alone or with 10-100 #g/ml of MDP or 10- 
200 #g/ml of poly IC/LC. Supernatants were harvested at 36 h and IFN-a activity measured. 
Data represent the mean and standard error of three separate experiments. STEVENSON  ET  AL.  507 
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FIGURE 2.  Human monocytes were cultured alone,  with  10-200/=g/mi of poly IC/LC or 
10-200 #g/ml of MDP. Supernatants were harvested at 36 h and incubated with 104 cultured 
fibroblasts per well to determine FGF activity by [SH]thymidine incorporation. Data represent 
the mean and standard error of three separate experiments.  Mean baseline proliferation for 
fibroblasts without added factors was 1.25 x  104 TCA-precipitable  cpm/104 cells. 
FIGURE 3.  A representative autoradiograph of messenger  RNA from monocytes after gel 
electrophoresis,  Northern  transfer onto nitrocellulose,  and  hybridization  for 72  h  with  a 
s~P-labeled cDNA for IFN-a (pLM001).  (1) Unstimulated  monocytes; (2) monocytes cultured 
for 18 h after stimulation  with 200 #g/ml of poly IC/LC; (3) monocytes stimulated  with 200 
pg/ml of MDP. The messenger RNA (~2 #g) from 400 million purified cells was loaded into 
each lane. Band size calculations (1.0-5.5 kb) are numerically indicated  on the left; the actual 
migration of  size markers (1.5 and 2.9 kb E. coli  and 1.7 and 4.9 kb human monocyte  ribosomal 
RNAs) are indicated  by arrows in the left margin. 
between  the  unactivated  vs.  MDP-activated  or  poly  IC/LC-activated  human 
monocytes (~ 110 pg of total RNA per  10  s monocytes [data not shown]). 
Hybridization  of IFN-a cDNA Probes to Human Monocyte Messenger  RNA.  Fig. 
3  demonstrates  a  representative  autoradiograph  of glyoxal-denatured  human 
monocyte poly(A)enriched RNA that has been separated by agarose gel electro- 
phoresis,  blotted  to nitrocellulose  sheets,  and hybridized to a  3~P-labeled  IFN-a 
cDNA probe (pLM001). The results indicated that, after  18 h  of culture, control 
(unactivated)  monocytes  (Fig.  3,  lane  1)  did  not  produce  detectable  levels  of 
IFN-a  mRNAs  that  were  hybridizable  to  the  IFN-a  cDNA  probe  used.  In 508  ALPHA INTERFERON GENE EXPRESSION IN HUMAN MONOCYTES 
FIGURE 4.  A representative  autoradiograph of serial fourfold dilutions of messenger RNA 
from monocytes hybridized for 72 h with either of two s2P-labeled  cDNA for IFN-a after dot 
blotting onto nitrocellulose. (A) Hybridization with pLM001.  (B) Hybridization with HulFN- 
a~. (1) 0.1 #g of denatured cDNA probe (pLM001 for A, HuIFN-~2 for B); (2) poly A-selected 
RNA from 100 million unstimulated monocytes; (3) poly A-selected RNA from 100 million 
monocytes  stimulated  with  10 #g/ml of poly IC/LC; (4) poly A-selected RNA from  100 
million monocytes stimulated for 18 h with 50 #g/ml of poly IC/LC; (5) poly A-selected RNA 
from 100 million monocytes stimulated  with 200 #g/ml of poly IC/LC. 250 ng of poly A- 
selected  RNA  was spotted  in  the  first  dot  position  of lanes  2-5,  followed by four,  serial, 
fourfold dilutions. 
contrast,  monocytes activated  with both poly IC/LC and MDP contained detect- 
able  IFN-a  mRNAs.  Monocytes  activated  with  poly  IC/LC  (Fig.  3,  lane  2) 
expressed  the  1.0  kb mRNA  normally  associated  with secreted  IFN-a  (28).  In 
addition, two higher molecular weight, novel RNA species (2.8 and 5.5 kb) were 
detected.  Monocytes  activated  with MDP (Fig.  3, lane 3) contained only 2.8  kb 
mRNA.  Similar  results  were  observed  in  three  separate  experiments  using 
different normal volunteers (data not shown). 
Dot blot hybridization (Fig. 4) revealed a dose-responsive  expression of IFN-a 
mRNA  in poly  IC/LC-stimulated  monocytes;  as the poly  IC/LC  concentration 
was increased  from  10 to 200 ~g/ml,  the size of the dots also increased.  Similar STEVENSON  ET  AL. 
TABLE  I 
IFN-ct Activity* Found in the Cell Lysates of Cultured Monocytes at 36 h and 72 h 
509 
Unstimulated  Poly IC/LC stimulated*  MDP stimulated! 
36 h  72 h  36 h  72 h  36 h  72 h 
Antiviral activity 
Antiviral activity after pH 2 
neutralization 
Antiviral activity after anti- 
IFN-a antibody neutraliza- 
tion 
<120  <120  1050__.2501  810±180  350±35  230±75 
NT  ~  NT  i ,020**  945  360  400 
NT  NT  <120  <120  <120  <120 
* Expressed as calculated units per milliliter of lysate (I 09 cells). 
* 200 #g/ml of poly IC/LC. 
g 200 #g/ml of MDP. 
I Represents mean _  SEM of four separate experiments. 
Not tested. 
** Average of two experiments. 
results were seen when the dot blots were probed with pLM00]  (Fig. 4A) or the 
HuIFN-a~ probe (Fig. 4B). 
Synthesis of Cytoplasmic IFN-a by Human Monocytes.  In an attempt to evaluate 
whether MDPoactivated monocytes (expressing 2.8 kb IFN-ot mRNA) might be 
synthesizing an unreleased cytoplasmic form of IFN-a, extensively washed con- 
trol and activated monocytes were lysed at 36 and 72 h, and IFN-a measurements 
performed on the cell lysate. As shown in Table I, control (unactivated) monocyte 
cell  lysates were consistently found to  be free of IFN-a activity at both  time 
points.  The  mean  IFN-a  activity  found  in  the  cell  lysates  of poly  IC/LC- 
stimulated monocytes (four experiments) was  1,050  __+ 250  U/ml at 36 h. The 
mean  IFN-a  activity found  in  the  monocyte cell  lysates after  36  h  of MDP 
stimulation (350  __+ 35  U/mt) was significantly lower (P <  0.05).  Intracellular 
IFN-a levels at 72 h  after either poly IC/LC or MDP stimulation were slightly 
lower than the levels observed at 36 h. This intracellular IFN-a activity was pH 
2 stable and neutralizable by anti-human leukocyte IFN antiserum. It was not 
possible to determine if any of the intraceilular IFN-a activity found in the poly 
IC/LC-stimulated cells was of the exclusively intracellular variety; some of the 
intracellular activity was likely being processed for secretion. 
Discussion 
We detected two species of IFN-ot mRNA with IFN-a probes in poly IC/LC- 
stimulated human monocytes that we did not detect in unstimulated monocytes 
or in MDP-stimulated monocytes. The  1.0 kb band is similar to the major size 
class  for  IFN-a  described  by  others  for  lymphoblastoid  cell  lines  (28).  The 
detection of higher molecular weight bands is also consistent with these previous 
studies. The relative proportions of the low and high molecular weight IFN-a 
mRNA forms of the stimulated human  monocytes observed here seem quite 
different from those observed in Sendal virus-induced Namalwa cells (28). This 
may indicate that the expression of the IFN-a family of genes differs in monocytes 
vs. lymphoblastoid cell lines and perhaps varies with the stimulatory agents used 
in  the two sets of experiments. We assume that the 2.8  kb and 5.5  kb species 510  ALPHA INTERFERON  GENE EXPRESSION IN HUMAN MONOCYTES 
detected here represent different primary transcripts, since the IFN-a genes lack 
introns and therefore should not be subject to intron splicing.  The origin of 
these high molecular weight species requires more direct investigation. 
Human monocytes activated by either MDP or poly IC/LC also contained a 
2.8  kb  IFN-a mRNA.  In human monocytes activated by MDP, which secrete 
FGF but not  IFN-a,  the 2.8  kb mRNA was the only IFN-ot mRNA detected 
under the hybridization conditions used in these experiments. The presence of 
a  2.8  kb  IFN-a  mRNA  appears  to  be  associated  with  the  presence  of an 
intracellular antiviral reactivity that was neutralizable by an antiserum specific 
for IFN-a, and was pH 2.0 stable.  However, we cannot exclude the possibility 
that very low amounts of another IFN-a mRNA (such as the 1.0 kb mRNA for 
IFN-a) may have gone undetected in the MDP-stimulated monocytes. It should 
be noted further that the 2.8 kb IFN-a, not the  1.0 kb IFN-a, was the major 
species of IFN-a mRNA present in the poly IC/LC-activated monocytes. Because 
of the relaxed hybridization conditions used and because there are many IFN-a 
genes that may vary in their homology to the IFN-ot cDNA we used (29), it is 
not certain if this is a true reflection of the quantities of different IFN-a mRNAs 
detected. It could be that the two IFN-ot probes used here are more homologous 
to the 2.8 kb mRNA so that a stronger hybridization signal was detected. The 
1.0  kb  mRNAs may also represent one or more different IFN-a  mRNAs of 
varying degrees of homology to the probes used in these experiments. A similar 
argument holds true for the 5.5 kb IFN-a mRNA. The mechanism for produc- 
tion of "nonsecretable" forms of IFN-a in MDP-stimulated human monocytes is 
not  known;  it  is  conceivable  that  the  2.8  kb  IFN-ot  mRNA  represents  the 
transcriptional product of one of the IFN-a pseudo-genes. 
The concept of the activated monocyte/macrophage has fascinated investiga- 
tors  worldwide.  Detailed  studies  of the  characteristics of animal  monocyte/ 
macrophages activated in vivo have produced extensive information regarding 
the functional characteristics (including monokine secretion) of the activated 
monocyte/macrophage (reviewed in  17-19); applications of this concept to the 
human monocyte situation have been anticipated. We propose here that the in 
vitro activated human monocyte might be composed of many monocyte  activation 
subset states, each state centering around a particular monocyte function (or set 
of functions). We postulate that the regulatory mechanisms controlling each of 
these various activation states in vitro are similar to those operating in vivo. In 
this paper, we present the results of the first human monocyte studies defining 
the transcriptional synthetic basis for IFN-a production. Our studies complement 
recent reports of success in analyzing human monocyte C~ mRNA metabolism 
(31). 
Our present studies may have potential direct clinical applications. A number 
of disease states are thought to reflect (at least in part) monocyte defects (reviewed 
in 32). Some of these diseases might be related to aberrations in the production 
of IFN-a or other monokines. A specific clinical problem that we are currently 
investigating focuses on those cancer patients who become unresponsive to poly 
IC/LC  immunotherapy in  vivo (33,  34).  Certain  of these patients  appear  to 
demonstrate defects in  IFN-a production.  This defect might be traced to  an 
abnormality in IFN-0t-related macromolecular synthesis by the patient's mono- STEVENSON  ET  AL.  511 
cytes. We feel that  the novel clinical and  laboratory technologies presented  in 
this report show the feasibility of further molecular biological studies in numerous 
activation and differentiation  states of human  monocytes, both in normal  indi- 
viduals and in patients. 
Summary 
Human monocytes were activated to secrete alpha interferon (IFN-a) by poly 
IC/LC but not by other monocyte activators, such as muramyl dipeptide (MDP). 
In contrast,  monocytes were activated to secrete fibroblast growth factor (FGF) 
release by MDP but not by poly IC/LC.  The amount of total  RNA present in 
unactivated and activated human  monocytes was similar.  Using two a2P-labeled 
cDNA probes (pLM001 and HuIFN-a~) for human IFN-a genes in hybridization 
studies, we analyzed messenger RNA species from this gene family in activated 
human monocytes. After activation with poly IC/LC, two other mRNA species 
(2.8  and  5.5  kb)  were  detected  in  addition  to  the  1.0  kb  mRNA  normally 
associated with IFN-a secretion.  Unexpectedly, monocytes activated with MDP 
also contained 2.8 kb IFN-a mRNA. There was associated with this 2.8 kb IFN- 
a  mRNA, found in MDP-activated monocytes, appreciable levels of intracellular 
IFN-ot activity in the absence of detectable secreted IFN-a.  Thus the secretion 
of IFN-a in activated human monocytes can be correlated with the appearance 
of a  1.0 kb mRNA species after poly IC/LC exposure. Secretion appears to be 
defective in MDP-stimulated  monocytes even though they contain active intra- 
cellular IFN-a apparently translated from the 2.8 kb mRNA. 
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